All News
A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ
Dr. Rachel Tate uptoTate ( View Tweet)
SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2020 press conference report: Global Rheum Alliance for COVID19 and Eular registries provide reassurance to rheums and pts regarding immunosuppression and COVID19. The compiled data from over 600 pts in 40 countries. @RheumNow
https://t.co/qMwGJTL041
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4
Dr. Rachel Tate uptoTate ( View Tweet)
Obesity is a strong predictor of worse clinical course and treatment response in AS. Poster #THU0389 #EULAR2020 @RheumNow https://t.co/Zb2RrqSIaK https://t.co/2z1HMQ3b5G
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Do you routinely discuss obesity with your rheum patients? #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
CEE= Central Easter Europe compared to US https://t.co/Zw4HPnZ8Id
Dr. John Cush RheumNow ( View Tweet)
nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396
https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
SEC shows improvement in both tender and swollen peripheral joints in AS pts. #EULAR2020 @RheumNow poster #THU0397
https://t.co/M0D6Ruh8ta https://t.co/kuShSUhXbf
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Thoughts on the #EULAR2020 e-congress? As a life long learner, I’ve enjoyed being able to attend but I miss my interactions with colleagues @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
This UK study to determine neutrophil function in PsA found that SEC does not affect neutrophil host defense. Check out #ABO115 for further details. An interesting find w/ regard to the inflammatory blockade and mediators of dz. #EULAR2020 @RheumNow https://t.co/EwLdlKU06A
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
IL-36 as a new biomarker/tx target in SpA? Check out this interesting in vitro study out of the UK and the IL-36 upstream induction of the IL-17/IL-23 pathway. #EULAR2020 @RheumNow #SAT0356 https://t.co/YTVepexd45
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3
Links:
Dr. Rachel Tate uptoTate ( View Tweet)